A series of microPET imaging studies were conducted in anesthetized rhesus monkeys using the dopamine D 3 -selective partial agonist, [ 
INTRODUCTION
Alterations in the dopaminergic pathways are thought to be involved in the etiology of a variety of neurological and neuropsychiatric disorders, including Parkinson's Disease, dystonia, and schizophrenia (Jardemark et al., 2002; Kapur and Mamo, 2003; Karimi et al., in press; Korczyn, 2003; Lee et al., 1978; Luedtke and Mach, 2003; Missale et al., 1998; Nieoullon, 2002; Perlmutter et al., 1997) . In addition, activation of the dopaminergic pathways may mediate the reinforcing effects of pyschostimulants, including cocaine and amphetamines (Nader et al., 1999; Uhl et al., 1998; Volkow et al., 2002) .
Molecular genetic studies have defined two types of dopamine receptors, the D 1 -like (D 1 and D 5 receptor subtypes) and the D 2 -like (D 2 , D 3 , and D 4 receptor subtypes), based upon structural and pharmacological similarities. D 1 -like receptors are structurally similar and positively linked to the activation of adenylyl cyclase via coupling to the G alpha(S) /G alpha(olf) class of G proteins (Herve et al., 2001) . Stimulation of the D 2 -like receptors results in the coupling with the G i /G o class of G proteins, leading to the inhibition of adenylyl cyclase activity (Sealfon and Olanow, 2000; Sibley and Monsma, 1992; Vallone et al., 2000) .
There is approximately 78% amino acid homology in the transmembrane spanning (TMS) regions of the D 2 and D 3 receptors that comprise the ligand binding site of these receptors (Sokoloff et al., 1990) . Despite the similarities in the structure of the D 2 and D 3 receptors, the D 2 and D 3 receptors differ in their (a) neuroanatomical localization, (b) levels of receptor expression, (c) efficacy in response to agonist stimulation, and (d) regulation and desensitization (Joyce, 2001; Luedtke and Mach, 2003; Mach et al., 2004) . Because of the high localization of D 3 receptors in limbic structures of the brain and the possibility that abnormalities in striatal D 3 receptors contribute to the pathophysiology of dystonia, there has been a concerted effort to develop D 3 -selective radiotracers for imaging the expression of this receptor in a variety of CNS disorders.
Previous efforts to image the D 3 receptor have focused on the preparation of radiolabeled analogs of the conformationally-flexible benzamide analogs including, RGH-1756 (Langer et al., 2000; Sovago et al., 2005) , the benzothiophene-2-carboxamide analog 1 (Kuhnast et al., 2006) , the benzofuran-2-carboxamide analog 2 (Turolla et al., 2005) , and [ 18 F]3, which is a 2-fluoroethoxy analog of FAUC 356 (Hocke et al., 2008) . However, the low uptake of these compounds in regions of the brain known to express D 3 receptors was attributed to the high lipophilicity of these analogs, which could cause low uptake in the CNS and high level of nonspecific binding for the amount of the radiotracer that does cross the bloodbrain barrier. Recently, a 11 C-labeled imidazolidinone analog, [ 11 C]4, was prepared and evaluated in vivo. This compound has a subnanomolar affinity for D 3 receptors and a 100-fold selectivity for D 3 versus D 2 receptors. The log P value of this compound is 2.9, which means that it should readily cross the bloodbrain barrier (Waterhouse, 2003) . Unfortunately, in vivo imaging in rhesus monkeys revealed no specific binding to D 3 receptors (Bennacef et al., 2009) .
In this study, we report the synthesis of [ (Dewey et al., 1992; Nader et al., 2006) .
MATERIALS AND METHODS Radiosynthesis
The synthesis of the mesylate precursor, 7, and unlabeled 5 (high-performance liquid chromatography (HPLC) standard) will be published separately. [ 2.2 in DMSO at 808C for 10 min. The final product was purified by reversed-phase HPLC (C-18 column; 52% methanol: 48% ammonium formate buffer) in 50% yield and a specific activity of 1500 Ci/mmol.
Receptor binding assays
In vitro binding assays were conducted using the assay conditions described by Chu et al. (2005) . The radioligand used in the binding assay was [ (Luedtke et al., 2000) .
Intrinsic activity assay
The intrinsic activity at dopamine D 3 receptors was determined using the cAMP assay conditions as described by Chu et al. (2005) . In this assay, quinpirole was used as a reference full agonist at both D 2 and D 3 dopamine receptors.
PET data acquisition
MicroPET imaging studies were conducted on a Focus 220 microPET scanner (Siemens Medical Systems, Knoxville, TN). Male rhesus monkeys (8-12 kg) were initially anesthetized with ketamine (10-15 mg/ kg) and injected with glycopyrrolate (0.013-0.017 mg/ kg) to reduce saliva secretions. PET tracers were administered 90 min after ketamine injection. Subjects were intubated and placed on the scanner bed with a circulating warm water blanket and blankets. A water-soluble ophthalmic ointment was placed in the eyes, and the head was positioned in the center of the field using gauze rolls taped in place. Anesthesia was maintained with isoflurane (1.0-1.75% in 1.5 L/ min oxygen flow). Respiration rate, pulse, oxygen saturation, body temperature, and inspired/exhaled gasses were monitored throughout the study. Radiotracers and fluids were administered using a catheter placed percutaneously in a peripheral vein. For the metabolism studies, a catheter was placed percutaneously in the contralateral femoral artery to permit the collection of arterial blood samples and for the determination of the blood time-activity-curve using a continuous flow detection system (Hutchins et al., 1986) . In each microPET scanning session, the head was positioned supine with the brain in the center of the field of view. A 10-min transmission scan was performed to check positioning; once confirmed, a 45-min transmission scan was obtained for attenuation correction. Subsequently, a 120-min dynamic emission scan was acquired after administration of 5 mCi of [ 18 F]5 via the venous catheter. For the lorazepam studies, animals were given an intravenous dose of the drug (1 mg/kg in saline) approximately 30 min before injection of the radiotracer. Blocking studies were also conducted in lorazepam-treated animals by administering compound 6 (1 mg/kg, i.v.), a structurally-related benzamide analog (Fig 1) , 5 min before tracer injection.
Time activity curves and metabolite analysis
Time activity curves for the initial 5 min postinjection were determined using the continuous flow detection system attached to a percutaneous arterial catheter. Arterial blood samples for metabolite analysis were taken in a heparinized syringe from the same catheter at 5, 15, 30, and 60 min post injection. The 5-min sample was taken immediately after the pump for the detector was turned off; the arterial line was flushed before collection of subsequent samples. Additional blood samples were taken at 45, 90, and 120 min for the TAC (Fig. 4C) . Metabolite analysis was performed using a solid-phase extraction technique previously used for similar studies (Mach et al., 1997) . A 1-mL aliquot of whole blood was centrifuged to separate plasma from packed red cells. Each fraction was counted, a 400-lL aliquot of plasma was removed, counted and deproteinated with 6 mL of 2: 1 methanol: 0.4 M perchloric acid mixture. The supernatant was diluted in 4 mL water and applied to an activated C-18 light Sep-Pak. The cartridge was neutralized with 2 mL 1N NaOH, then rinsed twice with water, and extracted with two portions of methanol (2 mL, 1 mL). All samples were counted in a Ludlum well counter. The methanol extracts were combined, concentrated in vacuo and rediluted to 150 lL of methanol for injection onto the HPLC. HPLC analysis was performed using a reversed-phase Phenomenex analytical column (Prodigy 250 3 4.6) with a mobile phase of methanol: 0.1 M ammonium formate buffer, pH 4.5 60:40. The flow rate was 0.8 mL/min, 0.5 min/ fraction and 36 fractions were collected and counted or each sample. The location of the parent UV peak was determined by injection of cold standard. The purity and stability of the injectate were confirmed by analysis of an in vitro control (reserved injectate added to a prescan blood sample and processed as described above after all the ex vivo samples were completed). This control also confirmed the stability of the radiotracer under the conditions used to process the blood for metabolite analysis. The percentages of unchanged parent compound and its metabolites were determined by decay correcting the counts and dividing the amount of recovered activity in all samples and multiplying by 100. (Table II ) Only a single peak for the parent compound was observed in the in vitro control and >95% of the activity was recovered.
Image processing and analysis
Acquired list mode data were histogrammed into a three-dimensional set of sinograms and binned to the following time frames: 3 3 1 min, 4 3 2 min, 3 3 3 min and 20 3 5 min. Sinogram data were corrected for attenuation and scatter. Maximum a posteriori (MAP) reconstructions were done with 18 iterations b 5 0. A 1.5 mm Gaussian filter was applied to smooth each MAP reconstructed image. These images were then coregistered with MRI images to identify the regions of interest with AnalyzeDirect software (AnalyzeDirect, Inc., Overland Park, KS). Threedimensional regions of interest were manually drawn through all planes of coregistered MRI images for the caudate, putamen, and cerebellum. The regions of interest were then overlaid on all reconstructed PET images to obtain time-activity curves. Activity measures are expressed as %ID/c.c. (Figs. 4A and 4B ).
RESULTS
In vitro binding studies indicate that 5 has a high affinity for D 3 receptors (0.17 nM) and 160-fold selectivity for D 3 versus D 2 receptors (Table I) . Functional assays demonstrated that 5 partially inhibited forskolin-dependent adenylyl cyclase activity relative to quinpirole (35% maximal response) in CHO cells transfected with hD 3 receptor ( Table I ), indicating that it is a partial agonist at D 3 receptors. These data are similar to that previously reported by our group for a diverse panel of N-phenyl piperazine analogs structurally similar to 5 (Chu et al., 2005) .
The synthesis of [ 18 F]5 was achieved in approximately 60 min in an overall radiochemical yield of 50% from starting [ 18 F]fluoride. The specific activity of the final compound was >1500 mCi/lmol (end of synthesis), which is suitable for microPET imaging studies (Fig. 2) .
MicroPET studies were conducted in rhesus monkeys under 1% isoflurane anesthesia (n 5 4). These initial microPET imaging studies yielded variable results (Fig. 3) , with one study demonstrating a high uptake in the caudate and putamen (monkey 4), but the other studies (monkeys 1-3) indicating no specific uptake of the radiotracer in regions of brain known to express D 3 receptors (Xu et al., 2009 (Xu et al., , 2010 . To determine if endogenous dopamine may be responsible for the variability of the PET results, a second series of studies were conducted in which the animal received an i.v. dose of lorazepam (1.0 mg/kg) 30 min before the injection of the radiotracer. Lorazepam was previously shown to increase striatal [ 11 C]raclopride binding (Dewey et al., 1992) , and we previously used this paradigm in our evaluation of the effect of endogenous dopamine to interfere with the binding of the D 2/3 radiotracer, [
18 F]FCP, in PET studies in rhesus monkeys (Nader et al., 2006) . The results of this study indicate that pretreatment with lorazepam eliminates the between-subject variability of the uptake of [ (Fig. 3) . There was also a notable increase in [ (Fig. 4) (Logan, 2000) . Lorazepam had no effect on the blood curve (Fig. 4) or metabolism (Table  II) Percent intrinsic activity (%IA) at human D 2 or D 3 receptors was determined using a forskolin-dependent adenylyl cyclase whole cell assay at a concentration of test compound < 10 3 K i value. The mean values (n > 3) were normalized to values obtained using the full agonist quinpirole. (Fig. 5) .
DISCUSSION
The development of PET radiotracers having a high selectivity for dopamine D 3 versus D 2 receptors has been an active area of research in recent years. Although a number of D 3 selective radiotracers, labeled with either carbon-11 (t 5 20.4 min) or fluorine-18 (t 5 110 min), have been reported over the past decade, none have proven to be useful for imaging this receptor in vivo. Consequently, studies aimed at imaging the D 3 receptor must resort to using nonselective, high D 2 /D 3 affinity radiotracers such as the radiolabeled antagonists [ In the current study, we present evidence demonstrating that [
18 F]5 is a potential radiotracer for imaging D 3 receptors in vivo with PET. [ 18 F]5 has a subnanomolar affinity for D 3 receptors and a 160-fold higher affinity for D 3 compared with D 2 dopamine receptors. An important observation in the current study is the ability of endogenous dopamine to compete with D 3 receptors in vivo to the extent that it is necessary to decrease synaptic levels of dopamine by pretreatment with lorazepam to image D 3 receptors in the anesthetized rhesus monkey. This observation is consistent with previous reports regarding the high in vivo occupancy of D 3 receptors by endogenous dopamine, including (1) the binding of [ 125 I]iodosuplride to D 3 receptors in autoradiography studies requires either extensive washing of tissue slices to remove endogenous dopamine, or the in vivo depletion of monoamines with tetrabenazine before euthanasia and tissue preparation (Schotte et al., 1992 (Schotte et al., , 1996 and (2) endogenous dopamine protects the D 3 receptor from alkylation by 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) and the spiperone analog, N-(p-isothiocyanatophenethyl)spiperone (NIPS), in vivo whereas no such protection was observed at D 2 receptors (Levant, 1995; Zhang et al., 1999) . Finally, several in vitro binding studies have revealed that dopamine has a higher affinity for cloned D 3 versus D 2 receptors (reviewed in Levant, 1997) , and supports a An unresolved question from the current study relates to the ability to image D 3 receptors in vivo without the need to deplete the dopaminergic synapse of endogenous neurotransmitter. It must be stressed that the current study was conducted under conditions of isoflurane anesthesia. Previous studies by Votaw et al. have shown that isoflurane increases the trafficking of the dopamine transporter (DAT) from the plasma membrane to the cell interior (Votaw et al., 2003 (Votaw et al., , 2004 , which may contribute to the increase in extracellular dopamine concentrations measured in microdialysis studies (Adachi et al., 2005; Tsukada et al., 1999) . Potentiation of GABAergic neurotransmission by pretreatment with lorazepam decreases activity of dopaminergic neurons (Dewey et al., 1992 (Christian et al., 2000; Rabiner et al., 2009) . In fact, one study reported that isoflurane anesthesia increased the binding of In summary, the results of the current study indicate that it is possible to image dopamine D 3 receptors in vivo with PET with [
18 F]5 even though this has not been demonstrated with structurally-related radiotracers. It should be noted that all of the radiotracers shown in Figure 1 have a similar high (i.e., subnanomolar) affinity for D 3 receptors and high selectivity for D 3 versus D 2 receptors (>100-fold). The key step taken in the current study was the use of lorazepam to reduce synaptic dopamine levels under conditions of isoflurane anesthesia, which should minimize competition between endogenous dopamine and [ 
